KiResearcher
BlendsWolverineWolverine Stack

Wolverine Blend

Fixed-ratio injury & soft-tissue blend · BPC-157 10 mg + TB-500 10 mg

Wolverine is a pre-mixed, single-vial blend of the two most-used recovery peptides — 10 mg of BPC-157 and 10 mg of TB-500 (Thymosin β4) — sold as one 20 mg powder in a fixed 1 : 1 ratio by mass. It is not a new molecule: each peptide keeps its own identity and pharmacology, and the blend simply lets one draw deliver both in the vial's proportions. It is the injury and soft-tissue member of the blend family — the copper-free pair, with no GHK-Cu to carry a metal into the vial (GLOW adds 50 mg of it; KLOW adds KPV on top of GLOW). The defining trade-off is scheduling: BPC-157's own protocols are daily and TB-500's are weekly, and a fixed 1 : 1 vial has to pick one. Dosed daily — the way Wolverine is actually run — BPC-157 lands squarely in its own range and TB-500 arrives as a steady drip rather than a weekly bolus. The evidence for each component is separate and, for injected use, overwhelmingly preclinical; no published study has tested the two together. Neither is an approved drug, and both are prohibited in sport (WADA).

TL;DRThe whole page · in 30 seconds

Injury recovery · Tendons & ligaments · Soft-tissue repair · Two peptides, one draw

The recovery stack in a single vial. Wolverine packs BPC-157's blood-supply-building repair and TB-500's repair-cell migration into one 20 mg vial at a straight 1 : 1 — the blend people reach for when a tendon, ligament, or muscle is the problem and two separate vials are the obstacle.

The basics

  • A pre-mixed powder: 10 mg BPC-157 + 10 mg TB-500 (a 1 : 1 ratio). One vial, one draw, both peptides every time.
  • The injury member of the blend family — the copper-free pair. GLOW adds GHK-Cu for skin and scars; KLOW adds KPV on top of that.

Why people use it

  • Heals tendons, ligaments, and muscle faster — BPC-157 grows fresh blood supply into the repair zone while TB-500 pulls repair cells in.
  • Two levers, not the same one twice — blood supply and cell arrival are different halves of the same job.
  • Works body-wide, not just at the needle — both peptides circulate, so the signal reaches tissue far from the injection.
  • One shot instead of two — the whole recovery duo in a single daily draw, at the dose BPC-157 wants.

How to run it

  • Dose: 5–10 units a day (500–1,000 mcg of blend = 250–500 mcg BPC-157 + 250–500 mcg TB-500); 3 units to start, 10 at the top
  • How often: Once daily — split 5 units AM + 5 units PM for an active injury
  • How: A small injection under the skin (belly fat) — one syringe covers both
  • When: Evening — rides your overnight repair window
  • Cycle: 4–6 weeks on, then 2–4 weeks off; one 20 mg vial is 20 days at 10 units

Stacks well with

  • A separate TB-500 vial — 10 units of Wolverine already delivers 3.5 mg of TB-500 a week; one extra 500 mcg–1 mg TB-500 shot weekly takes the total to 4–4.5 mg for a loading phase, without touching the BPC-157 dose.
  • KPV — 300–500 mcg daily when inflammation is part of the problem; with GHK-Cu in the mix as well, the pre-mixed answer is KLOW.

Good to know

  • The 1 : 1 ratio means one schedule for both: run daily and BPC-157 lands right in its own range while TB-500 arrives as a steady daily drip instead of the big weekly shot it's usually given as. Want a true TB-500 loading phase? Add a separate TB-500 vial.
  • Don't flip it to twice-weekly to suit TB-500 — a 2–2.5 mg TB-500 shot is 40–50 units of this blend, which carries 2–2.5 mg of BPC-157 in one hit and nothing for five days.
  • No copper in the vial, so none of the metal-and-methionine worry that follows GLOW and KLOW — and the usual zinc-plus-copper cofactor pairing works the normal way round here.
  • Banned in tested sport — BPC-157 and TB-500 are both on the WADA list.
  • TB-500 spurs blood-vessel and cell growth, so this blend is generally avoided by anyone with cancer concerns.
  • Once mixed, refrigerate and finish it within about 4 weeks — one 20 mg vial is 20 days at 10 units a day.
Bottom line: The one-vial answer for a soft-tissue injury — run it at 5–10 units a day in 4–6-week blocks, and add a separate TB-500 shot if you want a real loading phase.
01

Molecular identity

Specs

Composition
BPC-157 10 mg · TB-500 10 mg = 20 mg per vialCross-source vendor agreement
Ratio
1 : 1 by mass — 50 % BPC-157 · 50 % TB-500Calculated
Structure / class
Fixed-ratio, co-lyophilized blend of two research peptides in one vial — not a new molecule; each component keeps its own identity and pharmacologyCross-source vendor agreement
BPC-157 (10 mg)
GEPPPGKPADDAGLV (15 AA) · C62H98N16O22 · 1,419.5 g/mol · CAS 137525-51-0PubChem CID 9941957
TB-500 (10 mg)
Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (43 AA) · C212H350N56O78S · ~4,963 g/mol · CAS 77591-33-4PubChem CID 16132341
Vial size
20 mg standard (10 mg + 10 mg). Half-size 10 mg (5/5) and double-size 40 mg (20/20) vials of the same 1 : 1 recipe are also sold — mixed proportionally (1 mL and 4 mL) they all give 10,000 mcg/mL, so the ratio, not the vial size, is what the math depends onCross-source vendor agreement
Molecular target
Two separate targets — BPC-157 acts via the nitric-oxide / VEGFR2–Akt–eNOS angiogenic pathway; TB-500 sequesters monomeric (G-)actin 1:1, with downstream cell migration, angiogenesis, and NF-κB modulationPMID 27847966 · UniProt P62328
Half-life (per component)
No single clock — BPC-157 clears within minutes (<30 min, rat IV), TB-500 within roughly half an hour to two hours (~0.5–2 h, human IV, dose-dependent); the blend inherits two separate curves, not onePMID 36588717 · PMID 34346165 · PMID 20536472Half-life curve →
Regulatory status
Neither component is an approved drug; no trial has tested the two-peptide combination; both are prohibited in sport (WADA S0 / S2.3)FDA / WADA Prohibited List
02

Plain English

Mechanism

A blend is a packaging decision, not a new drug. Wolverine is one freeze-dried powder containing two separate peptides, so when you add water you get both in solution together and every draw carries them in the vial's fixed proportions — 10 parts BPC-157 to 10 parts TB-500 by weight, a straight 1 : 1. Nothing about that changes how either peptide works; it changes only how you measure them. It also removes the one chemistry argument that follows the copper blends around. The worry there is that copper attacks sulfur-containing amino acids — methionine and cysteine — in whatever it is stored with. BPC-157 (C62H98N16O22) contains no sulfur at all, so it was never vulnerable in the first place; TB-500 does carry one methionine, which is why a slow copper-driven oxidation is at least chemically arguable in a GLOW or KLOW vial. In a Wolverine vial there is no copper and no other redox metal, so there is nothing to drive that reaction at all. The only storage rule left is the one that applies to every reconstituted peptide: keep it cold and use it within about four weeks.

BPC-157 supplies the repair-and-blood-supply signal. A 15-amino-acid fragment of a protective gastric protein, it is studied for switching on angiogenesis — the growth of new blood vessels that feed a healing site — through the VEGFR2–Akt–eNOS pathway, with rodent and cell-culture studies reporting more VEGFR2 receptor, greater vessel density, and relaxation of the vessel wall so blood flows more easily. At the cellular level it speeds the migration of fibroblasts, the cells that build and repair connective tissue, by activating their FAK/paxillin traction machinery; it also raises the growth-hormone receptor on tendon cells and switches on EGR-1, a gene that drives new tissue laydown and the organized weaving of collagen.

TB-500 supplies the cell-arrival signal. It is the synthetic form of Thymosin β4, the body's principal actin-sequestering peptide: it binds single actin units one-to-one and holds them in reserve, regulating how fast a cell can build and dismantle the filaments that drive its movement. Research literature links that actin control to the migration of repair cells — fibroblasts, keratinocytes, and the endothelial cells that line blood vessels — into damaged tissue and to faster re-epithelialization, the regrowth of skin over a wound. Review work adds a pro-angiogenic arm (raising VEGF, the chief vessel-growth signal), an anti-inflammatory arm (blocking NF-κB), and an anti-fibrotic fragment (Ac-SDKP) the body clips off the end of the molecule. Both peptides circulate after a subcutaneous injection, so they act on distant tissue, not only around the needle.

Why people combine them is the complementarity: two different levers on one repair job — the blood supply and structural rebuild (BPC-157) and the arrival of the cells that do the rebuilding (TB-500). It is the most commonly co-drawn pair in practice, and the blend is simply that habit sold pre-mixed. Read the evidence level honestly, though. This is two separate, mostly animal and cell-culture evidence bases stacked side by side: no published study has tested BPC-157 and TB-500 together, in any model, at any ratio, so the synergy is reasoned from mechanism rather than shown in a trial — and the 10/10 recipe itself is a market convention, not a studied formulation. The second honest point is scheduling: the two components' own protocols run on different clocks — BPC-157 daily, TB-500 weekly — and a fixed 1 : 1 vial has to pick one. The dosing section below works out exactly what each choice delivers.

Sources:PubChem CID 9941957PubChem CID 16132341UniProt P62328PMID 27847966PMID 33051481PMID 21030672PMID 25415472PMID 17628536PMID 8506348PMID 25313062PMID 10469335PMID 15565145PMID 34992578

03

Why people reach for it

Potential benefits

Wolverine is the blend people reach for when an injury is the goal and they don't want two vials on the shelf. Here's what draws them to it.

  • Bounce back from tendon, ligament, and muscle injuries faster — The headline appeal, and the reason the pair exists: BPC-157 grows new vessels into a repair zone and speeds the fibroblasts that rebuild connective tissue, while TB-500 gets repair cells moving into the damaged tissue in the first place.
  • Two levers on the same job, not one twice — Blood supply and cell arrival are genuinely different halves of a repair. Stacking two angiogenesis peptides would double one signal; this pair covers more of the biology than either component does alone, which is why it's the most common recovery combination in practice.
  • One draw instead of two — The practical reason the blend exists: one vial, one reconstitution, one daily injection that delivers both peptides in a fixed ratio — fewer sticks, fewer vials to track, no separate mixing.
  • A whole-body repair signal, not just a local one — Both peptides circulate after a subcutaneous injection, so people use Wolverine for tendons, ligaments, and post-surgical recovery well away from the injection site, rather than having to inject at the sore spot.
  • The daily dose lands where BPC-157 wants it — At 5–10 units, BPC-157 sits at 250–500 mcg a day — exactly its own page's standard band — and TB-500 rides along at 1.75–3.5 mg a week. The blend suits BPC-157's schedule; TB-500 arrives as a continuous drip rather than a weekly bolus.
  • No copper to complicate the vial — Nothing in a Wolverine vial can oxidize TB-500's single methionine, so the storage question is the ordinary one, and copper stays a cofactor you control on the supplement side instead of a dose you're already receiving.

Sources:PMID 27847966PMID 25415472PMID 34829776PMID 36588717PMID 10469335PMID 15565145PMID 34992578

What people reach for Wolverine for, drawn from what each component's research reports (overwhelmingly cell-culture and animal work for injected use) and how the blend is used — no study has tested the two together, and none of this is a proven outcome or a medical claim.

04

Implied timing

Best time to dose

Implied best time

Evening

Most people inject Wolverine in the evening, lining both repair signals up with the body's overnight recovery window — the same call each component's own page makes.

  • Overnight is when the body does most of its rebuilding — deep sleep brings the natural growth-hormone pulse, peak tissue regeneration, and the least mechanical load on healing tissue. An evening dose puts BPC-157's vessel-growth signal and TB-500's cell-migration signal to work as that window opens.
  • Neither component has a circadian rule of its own. BPC-157 clears the blood in minutes (rat IV) and TB-500 in roughly half an hour to two hours (human IV), so the value is the repair signal each leaves behind. In the animal research, timing is set by the injury — dosing starts as close to the insult as possible — not by the clock.
  • Because the blend is one daily draw, a single consistent evening slot is the whole timing plan; morning works fine if evening is impractical. If you split it 5 units AM + 5 units PM for an active injury, space the two roughly 10–12 hours apart and treat the evening half as the more important of the two.

No study establishes an ideal time of day for Wolverine or for either of its components — this is reasoned from their mechanisms and how they're used. As a rule of thumb most peptide dosing lands in the midday-to-evening window; for Wolverine the lean is evening, to align with overnight repair.

Sources:PMID 36588717PMID 34346165PMID 10469335

05

How to run it

Dosing & protocol

Wolverine is dosed here as one subcutaneous injection a day, measured as total blend on a U-100 insulin syringe — the form it's sold in and the route every calculator on this site is built for. The defining fact of a blend is that you dose both peptides with one number: pick the units and the ratio decides how much of each you get. Because the ratio is a straight 1 : 1, the arithmetic is unusually clean — every draw is half BPC-157, half TB-500 — and the tiers below map almost exactly onto BPC-157's own three dose bands. Read it as a map of how people actually run Wolverine, not a validated prescription.

Community convention, not trial-proven: no study has tested the BPC-157 + TB-500 combination, BPC-157 has no controlled human dosing trial, and TB-500's systemic evidence is preclinical with no validated human dose. Neither is FDA-approved. Every number here is a usage pattern assembled from the two component pages — not a medical recommendation.

Tiered dose ranges (total blend per draw)

Standard mix: 20 mg vial + 2 mL bacteriostatic water = 10,000 mcg/mL, so 1 unit on a U-100 syringe = 100 mcg of blend — exactly 50 mcg BPC-157 + 50 mcg TB-500.

Low / first week — 3–5 units (300–500 mcg):
150–250 mcg BPC-157 + 150–250 mcg TB-500 once daily. That is BPC-157's own low band exactly, and puts TB-500 at 1.05–1.75 mg a week — as a weekly total, that sits inside the 0.5–2 mg a week spanned by the 500 mcg–1 mg once-or-twice-weekly light connective-tissue support band on its page. Used to check tolerance, or as maintenance between injuries.
Standard — 5–10 units (500–1,000 mcg):
250–500 mcg BPC-157 + 250–500 mcg TB-500 once daily — the working range, and the reason the blend exists in this ratio. BPC-157 lands across its full 250–500 mcg standard band, the range its page gives for tendon, ligament, muscle, and gut goals. TB-500 accumulates to 1.75–3.5 mg a week, which brackets its 2–2.5 mg once-weekly maintenance figure — delivered as seven small doses instead of one.
High / ceiling — 10 units (1,000 mcg), often split 5 AM + 5 PM:
500 mcg BPC-157 + 500 mcg TB-500 a day. Splitting it puts BPC-157 at 250 mcg AM + 250 mcg PM — precisely the acute-injury split its own page describes — and TB-500 at 3.5 mg a week, between its maintenance and loading levels. This is the blend's ceiling, and BPC-157 sets it: 500 mcg/day is where its own page stops, so more units means running one component past its range to feed the other. If the injury calls for loading-level TB-500, the honest move is a separate vial, not more Wolverine.

The cadence trade-off — why daily wins

The two components are dosed on different clocks on their own pages: BPC-157 250–500 mcg daily, TB-500 2–2.5 mg once or twice weekly. A fixed 1 : 1 vial can only honour one of them, and it is worth being explicit about which.

Daily dosing — what it actually delivers:
At 5–10 units a day, BPC-157 sits in its standard 250–500 mcg band, correct in both amount and schedule. TB-500 comes out at 250–500 mcg a day, or 1.75–3.5 mg a week — a weekly total inside its normal range, but delivered as a continuous drip rather than the weekly bolus its own protocols use. Neither pattern has a PK study behind it for systemic Tβ4 (its human trials are IV pharmacokinetics and safety only), so this is a reasoned trade-off, not a proven equivalence. It is how Wolverine is run.
Twice-weekly dosing — don't:
To give TB-500 a real 2–2.5 mg shot you would draw 40–50 units of this blend (0.40–0.50 mL at the standard mix). That same shot carries 2–2.5 mg of BPC-157 — four to five times its own daily ceiling in one hit — and leaves it absent on the other five days, which is the opposite of how BPC-157 is used. The blend is not the vehicle for TB-500's cadence.
Reaching a TB-500 loading phase:
TB-500's loading band is 2–2.5 mg twice weekly, or 4–5 mg a week. Ten units of Wolverine a day already supplies 3.5 mg a week, so one separate 500 mcg–1 mg TB-500 injection weekly brings the total to 4–4.5 mg — inside the loading band by weekly total, though still delivered as a daily drip plus one small bolus rather than the two boluses its page describes, with the BPC-157 dose untouched. Do not layer a full 2–2.5 mg twice-weekly TB-500 protocol on top of a daily blend; that would push the weekly total well past 5 mg. The cleaner alternative for a serious injury is separate vials for both peptides, where each dose moves independently.
Verdict:
Wolverine is the daily-dosing vehicle. It suits BPC-157's schedule exactly and delivers TB-500 as a continuous drip at a sensible weekly total. Pick it for the convenience of one draw a day; pick separate vials when you need either peptide to move on its own.

Subcutaneous administration

Wolverine is injected into subcutaneous fat; because it's one draw a day, site rotation and a consistent evening slot are the only execution choices.

Injection site:
Abdomen (a couple of inches clear of the navel), the love-handle area, or the outer thigh. Rotate sites between doses — local irritation and fatty lumps (lipohypertrophy) are what repeated use of one spot produces, and rotation is the fix. Injecting near the injured structure is a common user preference, not a requirement: both peptides circulate systemically.
Measuring the dose:
Drawn on a U-100 insulin syringe from the reconstituted vial. At the standard 20 mg + 2 mL mix: 3 units = 300 mcg · 5 units = 500 mcg · 7.5 units = 750 mcg · 10 units = 1,000 mcg of blend. Halve any of those for the per-component amount. The calculator on this page shows what each draw contains of both peptides, for any vial size or water volume.
Time of day:
Evening — see Best time to dose above. There is no circadian constraint, so a consistent daily time matters more than the exact hour; morning is fine if evening doesn't fit. For the AM/PM split, space the two doses roughly 10–12 hours apart.
Food window:
Subcutaneous injection; neither component competes with food for absorption. Inject independent of meals.

Cycle & washout

Both components run 4–6-week blocks on their own pages, and both are at their strongest started as close to the injury as possible — so the blend's cycle is simply theirs.

Acute-injury block:
4–6 weeks at 5–10 units a day, started as early as possible after the injury. That is BPC-157's acute cycle and the length of TB-500's loading phase at the same time. At 10 units a day one 20 mg vial lasts 20 days, so a 4-week block runs about a vial and a half and a 6-week block a little over two.
Maintenance block:
6–8 weeks at 3–5 units a day (150–250 mcg of each peptide), mirroring BPC-157's lower-dose chronic cycle. Watch the vial clock here: no draw at this tier empties a 20 mg vial inside the ~4 weeks a reconstituted vial should be used within — 3 units a day takes 67 days and 5 units takes 40. The half-size 10 mg (5/5) vial, mixed with 1 mL for the identical 10,000 mcg/mL, runs 33 days at 3 units and 20 days at 5 — so take the maintenance block from a 10 mg vial at 5 units, or accept discarding the last doses.
Washout:
2–4 weeks off after a 4-week block; take the full 4 weeks after a 6-week or longer run. Reassess the injury during the break — pain score, range of motion, or imaging where relevant — before deciding whether to repeat.
If the injury needs more TB-500:
Add one separate 500 mcg–1 mg TB-500 injection per week on top of 10 units of Wolverine, which brings the weekly TB-500 total to 4–4.5 mg. Beyond that, run both peptides from separate vials for the acute phase and keep the blend for the maintenance block.

Reconstitution at a glance

The on-page calculator does this live and splits every draw into its two components; the quick reference for the standard 20 mg vial:

Mixing (2 mL — the common convention):
20 mg vial + 2 mL bacteriostatic water = 10,000 mcg per mL. On a 100-unit (1 mL) insulin syringe: 1 unit = 100 mcg · 3 units = 300 mcg · 5 units = 500 mcg · 7.5 units = 750 mcg · 10 units = 1,000 mcg of blend. Every one of those splits exactly in half: 5 units is 250 mcg BPC-157 + 250 mcg TB-500.
Other vial sizes, same math:
A half-size 10 mg (5/5) vial with 1 mL, or a double-size 40 mg (20/20) vial with 4 mL, both land on 10,000 mcg/mL — so the unit-to-mcg conversion above holds unchanged. Mix proportionally and only the number of doses per vial changes, never the arithmetic. Just don't switch water volume mid-vial without redoing the math.
Why the split matters more than the total:
The syringe measures total blend, but each component's dose logic lives on its own page. The calculator's 'this dose contains' readout is the number to compare against those pages. The split assumes the standard 10/10 recipe; if your label lists a different ratio, this page's arithmetic doesn't apply to it.
Vial life:
At 10 units a day a 20 mg vial is 20 doses; at 5 units it is 40. Refrigerate once reconstituted and finish within about four weeks — which the 10-unit block does comfortably and the 5-unit block does not, so plan the vial size around the tier you intend to run.

Sources:PMID 27847966PMID 36588717PMID 20225319PMID 34829776PMID 10469335PMID 34346165PMID 20536472

06

Substrate the signal needs

Nutritional cofactor precision

Wolverine's two levers are angiogenesis and structural rebuild (BPC-157) and repair-cell migration (TB-500). The cofactors follow those levers: supply the collagen the arriving cells build with, feed the nitric-oxide system the vessel-growth signal runs on, and supply the trace minerals that cross-link the new collagen once it's laid down. Unlike the copper blends, nothing here is already in the vial — so this stack is the standard one both component pages describe, run the normal way round.

Reasoned from the two components' mechanisms plus general connective-tissue nutrition — not a Wolverine cofactor study. Supplement doses are common community ranges, not blend-specific findings.

Supply the collagen substrate

Both peptides signal for new tissue; this group supplies the raw material that signal builds with. Migration and angiogenesis lead nowhere without something to build.

Hydrolyzed collagen + vitamin C:
10–15 g hydrolyzed collagen peptides (Type I/III) with 500 mg vitamin C, ~30–60 min before activity or physical therapy. Vitamin C is the required cofactor for prolyl and lysyl hydroxylases — the enzymes that lock collagen into its stable triple helix — so without it the collagen signal has nothing finished to build with. One human study found vitamin-C–enriched gelatin taken pre-exercise doubled a blood marker of collagen synthesis.
Glycine, proline & total protein:
These two amino acids are the bulk of the collagen sequence. Adequate dietary protein (1.6–2.0 g/kg/day) keeps the pool replete and is the most common substrate bottleneck in injured people eating below maintenance; a 5–10 g/day glycine supplement is a common addition during the acute phase.

Amplify the NO / angiogenesis pathway

BPC-157 acts through the VEGFR2–Akt–eNOS axis and TB-500 raises VEGF; both depend on nitric oxide for the new vessels to dilate and actually perfuse the repair.

L-arginine or L-citrulline:
L-arginine 3–6 g/day or L-citrulline 3 g/day — citrulline converts more efficiently and skips first-pass gut degradation. Arginine is the direct substrate for eNOS, the enzyme that makes nitric oxide, which is the same pathway BPC-157 is activating. Morning or pre-workout, on an empty stomach; skip if blood pressure runs low.

Supply the cross-linking minerals — and here copper is yours to add

Once new collagen is laid down, lysyl oxidase welds it into durable tissue, and that enzyme requires copper. This is the group where a copper-free blend genuinely changes the protocol.

Zinc 15–30 mg:
Zinc picolinate or bisglycinate daily, with food. Zinc is the cofactor for the matrix metalloproteinases that clear damaged matrix and shape the remodel; deficiency lets scar tissue accumulate in place of organized repair.
Copper 1–2 mg — unlike GLOW, add it here:
1–2 mg copper bisglycinate daily alongside the zinc, the pairing both component pages call for. On GLOW or KLOW this is the one cofactor you skip, because the vial already injects copper past the gut's usual regulation. Wolverine carries none, so the ordinary rule applies: long courses of zinc without copper deplete copper status and stall the lysyl oxidase cross-linking step. Take copper at a different time of day from the zinc.

Sources:PMC2589959PMID 27852613PMID 9587142PMC5793244PMID 27847966PMID 33051481

07

Combinations + timing

Stacking notes + timing windows

Wolverine already stacks the two complementary repair mechanisms most people want, so the useful additions come from a different angle entirely — inflammation control, collagen and matrix remodeling, or simply un-fixing the ratio when TB-500 needs to go higher than a daily blend can take it.

User combinations reasoned from complementary mechanisms — not regimens studied head-to-head, and the blend itself has never been studied. Doses are community convention; "reached for" describes where users go, not a proven indication.

Wolverine + a separate TB-500 top-up

Un-fixing the ratio — the standard answer when an injury wants a real TB-500 loading phase and the daily blend can't reach it.

Why it works:
The blend's ceiling is set by BPC-157, which stops at 500 mcg/day on its own page. That caps TB-500 at 3.5 mg a week — just under its own 4–5 mg/week loading band. Adding TB-500 from its own vial raises only the component that needs raising, and leaves the BPC-157 dose exactly where it belongs.
The protocol:
Wolverine 10 units daily, plus one separate 500 mcg–1 mg TB-500 injection per week, bringing the weekly TB-500 total to 4–4.5 mg for the first 4–6 weeks of an acute injury. Rotate sites; the top-up can be co-drawn with the daily dose. Don't add a full 2–2.5 mg twice-weekly loading protocol on top — that overshoots the band.
Outcome:
Reached for on a fresh tendon, ligament, or post-surgical injury where the loading phase matters and the convenience of the blend is still worth keeping for the daily BPC-157.

Wolverine + KPV

An anti-inflammatory brake on top of the two repair signals — a different lever, not a third repair signal.

Why it works:
KPV is carried inside gut and immune cells and turns down NF-κB, the master inflammatory switch, so the repair Wolverine signals for happens in calmer tissue with less scarring. TB-500 dampens NF-κB to a degree as one of its reviewed mechanisms, but KPV's entire purpose is that brake. Repair versus inflammation control — complementary, not redundant.
The protocol:
Wolverine 5–10 units daily + KPV 300–500 mcg subcutaneously once daily, co-drawn or at a second nearby site, run through the acute phase and then tapered as swelling resolves. There is no pre-mixed Wolverine-plus-KPV vial — the four-peptide KLOW adds GHK-Cu as well, so choose it only if you want the copper peptide too.
Outcome:
Reached for on injuries with a significant inflammatory component — acute sprains, tendinopathy, post-surgical swelling — where calming the environment matters as much as the repair signal itself.

Wolverine + GHK-Cu (or just run GLOW)

Adds copper-peptide collagen remodeling and skin/connective-tissue quality to the repair pair — the third lever the copper blends were built around.

Why it works:
GHK-Cu independently drives collagen and matrix synthesis and delivers the copper that lysyl oxidase uses to cross-link new fibers into durable tissue. Where Wolverine's two peptides govern blood supply and cell arrival, GHK-Cu governs the quality of what gets built — different pathway, convergent outcome, and evidence in skin and wound contexts the other two lack.
The protocol:
Wolverine 5–10 units daily + GHK-Cu 1–2 mg subcutaneously daily, injected at separate rotated sites. If you're running all three every day anyway, the pre-mixed answer is GLOW — 10 units of it delivers 333 mcg each of BPC-157 and TB-500 — a third less than Wolverine's 500 mcg, though still inside BPC-157's own 250–500 mcg standard band — plus 1.67 mg of GHK-Cu in one draw. Keeping them separate is worth it only when you want to move the BPC-157 and TB-500 doses without dragging the copper load along.
Outcome:
Reached for when scar quality, skin, or post-surgical remodeling matters alongside the injury itself, rather than healing speed alone.

Sources:PMID 34992578PMID 27847966PMID 17628536PMID 9587142

08

Reconstitution math

Reconstitution calculator

Reconstitution calculator

Calculated for a 1 mL U-100 insulin syringe (100 units/mL).

mg
mL

Units per dose

5

Draw to this mark on a U-100 syringe

This dose contains

  • BPC-157250 mcg
  • TB-500250 mcg

Fixed ratio — every draw carries all of the vial's peptides in the same proportions; only the total changes.

Volume per dose
0.05 mL
Doses per vial
40
Concentration
10 mg/mL

One vial lasts

Daily
40 days
Every other day
80 days
5×/week
56 days

Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.

09

From the studies

Side effects from research

There is no safety study of Wolverine itself, so the safety picture is the two component pictures laid side by side — and neither is a human injectable dataset for this use. BPC-157's formal animal toxicology (mice, rats, rabbits, dogs) reported good tolerability with no lethal dose found, no signs of DNA damage or harm to fetal development, and only a small, reversible dip in creatinine — a kidney-function blood marker — in dogs at high doses. Full-length Thymosin β4 was well tolerated in human Phase I intravenous trials up to 1,260 mg with no dose-limiting toxicities or serious adverse events, and its Phase III eye-drop trial reported mostly mild eye-related effects. Neither dataset covers long-term subcutaneous use of either peptide, let alone of the two together.

One caution is specific to running them as one fixed-ratio vial: you cannot adjust either component without moving the other. If a reaction shows up, the only levers are to lower the whole dose or leave the blend for separate vials — which is also the reason the page's ceiling is written where BPC-157's is, not where TB-500's would allow. What Wolverine does not carry is a metal: with no copper in the vial there is no injected-copper load to account for, and nothing to oxidize TB-500's single methionine in storage, so the ordinary refrigerate-and-finish-in-four-weeks rule is the whole storage story.

The cautions that carry over unchanged: because TB-500 promotes both new blood-vessel growth and cell migration — the same activities that can feed a tumor — its relationship to cancer growth and metastasis is unresolved in the literature, with both tumor-suppressing and tumor-spreading findings reported across different models, so people with an active or recent cancer generally avoid it and therefore Wolverine. BPC-157 and TB-500 are both prohibited in sport by WADA at all times. Injection-site irritation and fatty lumps from repeated use at one spot are the usual practical complaints with any daily subcutaneous peptide; site rotation is the fix. This safety picture is preclinical for injected systemic use — none of it is human trial evidence for this route.

Sources:PMID 32334036PMID 34346165PMID 20536472PMID 36613994PMID 34992578WADA

10

As reported in literature

Research dosing ranges

There is no research dose for Wolverine because there is no research on Wolverine: no published study has tested BPC-157 and TB-500 together in any model. Beyond that, BPC-157 has no controlled human dosing trial, and full-length Thymosin β4 has no validated systemic human dose — its human trials are intravenous pharmacokinetic and safety studies only. What exists is two separate evidence bases, and the practical figures above lean on each component page's cited ranges. The rows below pull the load-bearing study doses from those pages so the evidence behind each component is visible here — shown separately so research data is never mistaken for a human dose. Mostly rodent; per kilogram of body weight (1 kg ≈ 2.2 lb) where the studies report it that way.

DoseRouteModelOutcomeSources:
AnySubcutaneous— no study of the two-peptide blendNo published study has tested BPC-157 + TB-500 together; the 10/10 vial ratio is a market convention, not a studied formulation
10 µg/kgIntraperitonealRat (ligament) — BPC-157Ligament healing + biomechanicsPMID 20225319
10 µg/kgIP / oral (drinking water)Rat (myotendinous) — BPC-157Functional + microscopic recoveryPMID 34829776
20–500 µg/kgIV & IMRat (PK) — BPC-157Pharmacokinetics (n=6/group)PMID 36588717
Topical / IPTopical / IPRat (dermal wound) — TB-500+42% re-epithelialization (d4), +61% (d7)PMID 10469335
IP / intramyocardialIP / intramyocardialMouse (myocardial infarction) — TB-500Improved cardiac function after infarctionPMID 15565145
0.05–25 µg/kgIntravenousHuman (Phase I PK/safety, n=84) — TB-500Dose-proportional PK; no dose-limiting toxicityPMID 34346165
42–1260 mgIntravenousHuman (Phase I PK/safety, n=40) — TB-500Dose-proportional PK; well toleratedPMID 20536472
11

Quick answers

Frequently asked

What exactly is in a Wolverine vial?

The standard 20 mg vial contains 10 mg BPC-157 and 10 mg TB-500 (full-length Thymosin β4), freeze-dried together in a fixed 1 : 1 ratio by weight. It is a packaging of two known peptides, not a new molecule. Half-size 10 mg (5/5) and double-size 40 mg (20/20) vials of the same recipe are also sold — check the label's ratio, because this page's arithmetic assumes 1 : 1.

How much of each peptide is in 10 units?

At the standard mix (20 mg + 2 mL bacteriostatic water = 10,000 mcg/mL), 1 unit on a U-100 insulin syringe is 100 mcg of blend, so 10 units is 1,000 mcg: exactly 500 mcg BPC-157 and 500 mcg TB-500. Because the ratio is 1 : 1, every draw simply splits in half. The calculator on this page shows the split for any draw, vial size, or water volume.

BPC-157 is dosed daily and TB-500 weekly — how does a 1 : 1 blend handle that?

By picking daily, which is how Wolverine is actually run. At 5–10 units a day BPC-157 sits in its own 250–500 mcg standard band, and TB-500 accumulates to 1.75–3.5 mg a week — a normal weekly total, just delivered as seven small doses instead of one bolus. Flipping to a twice-weekly schedule to suit TB-500 is the wrong move: a 2–2.5 mg TB-500 shot is 40–50 units of blend, which carries 2–2.5 mg of BPC-157 in one hit and none for five days. If you want a genuine TB-500 loading phase, add one separate 500 mcg–1 mg TB-500 injection a week on top of 10 units, or run both peptides from separate vials.

Wolverine vs GLOW vs KLOW — which one?

They nest. Wolverine is BPC-157 + TB-500, the injury pair with no copper peptide; GLOW adds 50 mg GHK-Cu for skin, scar, and matrix remodeling; KLOW adds 10 mg KPV on top of GLOW for reactive or inflamed skin. If the goal is a tendon or ligament, Wolverine lets you run BPC-157 and TB-500 at their own numbers without dragging a copper load up with them; if the goal is skin, GLOW; if the skin is also inflamed, KLOW. For a growth-hormone backdrop underneath any of them, the pre-mixed CJC-1295 / Ipamorelin blend is a different axis entirely.

Does the copper problem people warn about apply to Wolverine?

No, and it never did to BPC-157 either. Copper attacks sulfur-containing amino acids — methionine and cysteine — and BPC-157 (C62H98N16O22) contains no sulfur at all. TB-500 does carry one methionine, which is why the question is at least arguable in a copper-containing blend. Wolverine contains no copper and no other redox metal, so there is nothing to drive that reaction. Refrigerate the reconstituted vial and finish it within about four weeks, the same rule as any peptide.

Is Wolverine an approved drug?

No. Neither component is an approved drug, no trial has ever tested the combination, BPC-157 has no controlled human dosing trial, and full-length Thymosin β4 has no validated systemic human dose — its human trials are intravenous pharmacokinetic and safety studies. Both are prohibited in sport by WADA. This page presents research literature and community usage only and makes no therapeutic claims.

12

Primary sources

References

  • PubChem CID 9941957PubChem CID 9941957 (BPC-157; C62H98N16O22 — no sulfur, so no methionine/cysteine to oxidize)
  • PubChem CID 16132341PubChem CID 16132341 (Thymosin β4 / TB-500; one methionine, no cysteine)
  • UniProt P62328UniProt P62328 (human Thymosin β4 / TMSB4X)
  • PMID 27847966J. Mol. Med. 2017 (BPC-157 — VEGFR2/angiogenesis)
  • PMID 33051481Sci. Rep. 2020 (BPC-157 — NO/eNOS pathway)
  • PMID 21030672J. Appl. Physiol. 2011 (BPC-157 — fibroblast FAK/paxillin migration)
  • PMID 25415472Molecules 2014 (BPC-157 — growth-hormone receptor on tendon cells)
  • PMID 17628536Eur. J. Pharmacol. 2007 (BPC-157 — EGR-1 and collagen laydown)
  • PMID 20225319J. Orthop. Res. 2010 (BPC-157 — rat ligament healing)
  • PMID 34829776Biomedicines 2021 (BPC-157 — rat myotendinous recovery)
  • PMID 36588717Front. Pharmacol. 2022 (BPC-157 — rat/dog pharmacokinetics)
  • PMID 32334036Regul. Toxicol. Pharmacol. 2020 (BPC-157 — formal animal safety/toxicology)
  • PMID 8506348PNAS 1993 (Tβ4 actin ATP/ADP affinity)
  • PMID 25313062PNAS 2014 (structural basis, Tβ4–actin)
  • PMID 15565145Nature 2004 (Tβ4, ILK/Akt, cardiac repair)
  • PMID 10469335J Invest Dermatol 1999 (Tβ4 wound healing, rat)
  • PMID 34992578Front. Endocrinol. 2021 (Tβ4 function & application review)
  • PMID 34346165J Cell Mol Med 2021 (Phase I rhTβ4, IV PK/safety)
  • PMID 20536472Phase I synthetic Tβ4, IV PK/safety
  • PMID 36613994RGN-259 Phase III neurotrophic keratopathy (Tβ4 eye drops)
  • PMC2589959Ascorbate & collagen (review)
  • PMID 27852613Shaw et al. 2017 (vitamin-C–enriched gelatin & collagen synthesis)
  • PMID 9587142Rucker et al. 1998 (copper and lysyl oxidase cross-linking)
  • PMC5793244Zinc in wound healing (review)
  • WADAWADA Prohibited List (BPC-157 S0; Thymosin β4 S2.3 — prohibited at all times)

Reviewed by Ki Researcher Team · Research use only · Not medical advice · Updated 2026-09-01